Fundz

Regeneron Completes Acquisition Of Decibel Therapeutics, Adding Promising Gene Therapy Programs For Hearing Loss

PUBLIC · REGNSep 25, 2023

Acquiring Company

Regeneron

Acquired Company

Decibel Therapeutics, Inc.

TarrytownMassachusettsBiotechnologyHealth CareScience And EngineeringTherapeuticsBiotechnologyHealth CareTherapeutics

Description

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs.

Who to call at Regeneron, and when

When Regeneron changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Regeneron raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Regeneron, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Regeneron. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Regeneron

Location

777 Old Saw Mill River Road

Tarrytown, New York, United States

About

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Regeneron makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Regeneron's next move

Learn about Strategic plan

Frequently asked

Who acquired Decibel Therapeutics, Inc.?

Decibel Therapeutics, Inc. was acquired by Regeneron, based in Tarrytown. The deal was reported on September 25, 2023. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Regeneron is publicly traded (REGN) and operates in Biotechnology.

When did Regeneron acquire Decibel Therapeutics, Inc.?

Regeneron's acquisition of Decibel Therapeutics, Inc. was reported on September 25, 2023. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Decibel Therapeutics, Inc. do?

Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. It is privately held, operating in Biotechnology, and is based in Massachusetts.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.